Principles and practice of HIV-protease inhibitor pharmacoenhancement.

Abstract excerpt

Continually maintaining maximally suppressive drug concentrations represents a key defence against the emergence of resistance. If drug levels fall and replication occurs, the opportunity for mutant virus to be selected occurs. It has been increasingly recognized that variability in the pharmacokinetics of antiretrovirals, particularly protease inhibitors (PIs), means that drug exposure is not always optimal,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Anti-HIV Agents
• Share to Biological Availability
• Share to Drug Interactions